Travere Therapeutics Inc
NASDAQ:TVTX
Travere Therapeutics Inc
NASDAQ:TVTX
Price:
6.06 USD
-9.42%
Market Closed
Updated:
May 18, 2024
Travere Therapeutics Inc
Research & Development
|
Travere Therapeutics Inc
Research & Development Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Travere Therapeutics Inc
NASDAQ:TVTX
|
Research & Development
-$294.8m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-36%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$7.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.5B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-14%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$4.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-17%
|
See Also
What is Travere Therapeutics Inc's Research & Development?
Research & Development
-294.8m
USD
-294.8m
USD
Based on the financial report for Mar 31, 2024, Travere Therapeutics Inc's Research & Development amounts to -294.8m USD.
What is Travere Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-36%
-36%
Over the last year, the Research & Development growth was -31%. The average annual Research & Development growth rates for Travere Therapeutics Inc have been -26% over the past three years , -18% over the past five years , and -36% over the past ten years .
You don't have any saved screeners yet
